(Q36409144)

14 August 2017

1 reference

title

Impact of medical treatments for benign prostatic hyperplasia on sexual function (English)

1 reference

14 August 2017

main subject

prostatic hypertrophy

1 reference

Francois Giuliano

1

1 reference

14 August 2017

publication date

1 April 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

97 Suppl 2

1 reference

14 August 2017

page(s)

34-8; discussion 44-5

1 reference

Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06104.X

AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06104.X

EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06104.X

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06104.X

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06104.X

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06104.X

Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06104.X

Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06104.X

Cavernous nerve reconstruction with a biodegradable conduit graft and collagen sponge in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06104.X

A comparison of the effects of tamsulosin and alfuzosin on neurally evoked increases in bladder neck and seminal vesicle pressure in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06104.X

Evaluation of tamsulosin and alfuzosin activity in the rat vas deferens: relevance to ejaculation delays

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06104.X

D2-like receptors mediate the expulsion phase of ejaculation elicited by 8-hydroxy-2-(di-N-propylamino)tetralin in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06104.X

10.1111/J.1464-410X.2006.06104.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference